source
- Immunotherapy startup Adecto shuts down, citing risk-averse funding climateAdecto Pharmaceuticals, a Boston-based immunotherapy biotech founded in 2014 by Tufts researchers, announced it is closing after 12 years. The company had been developing AD100, a monoclonal antib…
- NIH launches streamlined website consolidating 700 sites into eight thematic hubsNIH announced a new version of its public website that reorganizes content from more than 700 separate sites into eight thematic hubs. The hubs cover health, research, data, clinical studies, rare…